Figure 13.

The exosome-related risk model as a potential predictor for chemosensitivity. (A–E) The respective IC₅₀ value of chosen compounds in relation to the risk score, as shown by Pearson’s correlation analysis (sunitinib, pralatrexate, copanlisib, acetalax, and bisacodyl) appeared to associate significantly with the exosome-related risk model (|Pearson’s correlation|>0.25 and p < 0.05). (F) Those with high-risk scores were found to possess lower IC₅₀ scores for FDA-approved chemotherapeutics such as sonidegib (p < 0.05). (G, H) Those with low-risk scores were indicated to possess lower IC₅₀ scores for medications including pipobroman and mithramycin (p < 0.05). The p-values were calculated using the Wilcoxon’s test.